Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Zoe Vanderweide Zoe Vanderweide is a writer focused on style and ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

The use of Sanofi’s Dupixent in atopic dermatitis has set a high benchmark for competitors within the space. Credit: marishkaSm via Shutterstock. Sanofi’s participation at the JP Morgan 43rd Annual ...

Sanofi’s chief executive Paul Hudson discussed the success of Dupixent (dupilumab)and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Furthermore, the successful launch of Dupixent for chronic obstructive pulmonary disease (COPD) has garnered significant coverage from top commercial and Medicare payers, indicating strong market ...

Such apps aren't discoverable through Play Store search and typically aren't optional, so the ability to leave a review never made much sense to begin with. If you've got a problem with a ...